Case Report {#sec1_1}
===========

A 74-year-old male presented unconscious to a small community hospital in florid shock. Following prompt intubation and initial hemodynamic stabilization the patient was transferred to our cardiac intensive care unit for a presumed devastating cardiac event. On arrival the patient was found to be in extremis with his initial objective presentation listed in [table 1](#T1){ref-type="table"}. A history was obtained from the patient\'s wife who stated that the patient was in his usual state of health until two weeks prior when his reactive airway disease began to worsen with the progression of winter.

For the past 67 years the patient had been taking Karo syrup with ephedrine (Forcalide syrup) every day to treat his reactive airway disease. The patient had carried the diagnosis of reactive airway disease following the accidental ingestion of gasoline at age 7. Since that time his local pharmacist has prepared the Karol-Ephedrine syrup, which the patient later described had 'always' successfully treated the symptoms of his airway disease. When the patient\'s symptoms began to worsen two weeks prior to his admission, he doubled his daily intake of the Karol-Ephedrine syrup. During the first week his respiratory system improved and the patient was able to return to his usual daily activities. However, during the second week, one week prior to admission, he began experiencing a dull epigastric pain that progressed to periodic bouts of extreme pain. The patient\'s pain was associated with fever and anorexia, however, he continued to consume the double dose of Karol-Ephedrine syrup. On the morning of presentation the patient\'s wife found him disoriented, febrile, and experiencing constant extreme abdominal pain.

After initial evaluation by our cardiac critical care colleagues, the diagnosis of septic shock was made with suspicion of an abdominal source. On our initial evaluation he was intubated, sedated but not chemically paralyzed. His abdomen was rigid and markedly distended. His wife reported progression of the severe episodes of epigastric pain. A STAT portable chest and abdominal radiograph demonstrated a massively dilated stomach with decompressed loops of small bowel ([fig. 1](#F1){ref-type="fig"}). A nasogastric tube was placed, which immediately released a rush of air and 200 ml of blood-stained bilious fluid.

The patient was emergently taken to the operating room for exploratory laparotomy. Upon initial abdominal exploration, more than 3 liters of transudative ascites was evacuated which revealed the obvious cause of the patient\'s sepsis and acute abdomen. The stomach was decompressed due to the placement of a nasograstic tube preoperatively, but showed extensive necrosis extending along the greater curvature and dependent portion of the body of the stomach ([fig. 2](#F2){ref-type="fig"}). Close inspection of the stomach revealed multiple microperforations along the greater curvature where the necrosis was most severe. Interestingly, palpable pulses were present in the vessels supplying the greater curvature of the stomach and there was no evidence of visceral vascular occlusive disease. With the extent of gastric insult a subtotal gastrectomy was required and his intestinal continuity was restored with a Roux-en-Y cardiojejunostomy. The patient tolerated the procedure well and was successfully discharged from the hospital. He discontinued his use of the Karol-Ephedrine syrup and did not have complications associated with gastrointestinal ischemia anymore.

Postoperatively we investigated the cause of the patient\'s unusual isolated gastric ischemia. Along with a more extensive history, as detailed above, we obtained a sample of the patient\'s Karol-Ephedrine syrup and tested the liquid along with the patient\'s serum for the presence of illegal substances and the presence of ephedrine ([table 2](#T2){ref-type="table"}). The sample of the syrup was submitted for gas chromatography/mass spectrometry (GC/MS) screening. A 2.0 ml sample of the Karol-Ephedrine syrup was combined with 100 μl of an internal standard solution (0.2 mg/ml benzocaine and 0.2 mg/ml cyheptamide), acidified with 1 ml buffer (pH 4.0) and extracted into 6 ml ethyl acetate/chloroform (20:80 v/v). Extracts were dried under 30°C nitrogen and reconstituted in 100 μl of pyridine/hexane (10:90). Using an Agilent 5973/6890 GC/MS, 1 μl of reconstituted sample was injected onto a DB-5MS column and subjected to gas chromatographic separation. Drugs present were identified by chromatographic retention time compared against a mixture of drug standards, and by structural analysis provided by mass spectrometry \[[@B1]\]. Of the tested substances known to cause vasoconstriction or gastric mucosal injury, ephedrine was the only substance that was found to be present in the patient\'s Karol-Ephedrine syrup and his serum. Hematoxylin and eosin staining of the gastrectomy specimen demonstrated the presence of chronic gastritis, microvascular thrombosis with full thickness necrosis, and multiple gastric perforations.

Discussion {#sec1_2}
==========

Ephedra is an alkaloid chemical compound obtained from the *Ephedra sinica* plant \[[@B2]\]. In traditional Chinese medicine this plant has been used for millennia to treat disorders such as asthma, upper respiratory illnesses and seasonal allergies \[[@B3]\]. In recent years Ephedra has gained tremendous popularity as a diet drug because of its biochemical activity as a stimulant and a prothermogenic agent \[[@B2],[@B4]\]. The stimulant activity of Ephedra suppresses appetite while the prothermogenic property increases the body\'s metabolism, all leading to improved weight loss \[[@B5]\]. However, over the past decade a number of well-documented reports of ischemic stroke and adverse cardiac events linked to Ephedra have lead to a FDA ban of the drug in April 2004 as a dietary supplement \[[@B2], [@B4], [@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\].

Ephedra causes a number of physiologic effects in addition to suppressing appetite and increasing metabolism \[[@B2], [@B3], [@B5], [@B12]\]. Ephedra causes an increase in blood pressure, heart rate and bronchial dilation \[[@B4], [@B7], [@B8], [@B11], [@B12], [@B13]\]. The effect of Ephedra on the vasculature is also well documented and comes from the drugs ability to function as a vasoconstrictor \[[@B8], [@B12], [@B13]\]. This effect as a potent vasoconstrictor has lead to the above listed cardiac and cerebral blood flow complications. However, to date no study or case report has shown Ephedra to cause microvascular thrombosis and intestinal necrosis.

The literature contains relatively few examples of isolated gastric ischemia from chemical sources. Ethanol, aspirin and other vasoactive compounds have been implicated in inducing isolated microvascular ischemia in the stomach \[[@B14],[@B15],[@B16],[@B17],[@B18]\]. Ethanol is thought to induce gastric ischemia by stimulating the release of endothelin-1, which is a potent vasoconstrictor \[[@B16],[@B17],[@B18]\]. Aspirin has been shown to reduce local blood flow, leading to microvascular ischemia and gastric mucosal injury \[[@B14], [@B15], [@B19], [@B20]\].

We conclude that the Ephedra in the patient\'s Forcalide syrup lead to severe vascoconstriction with resultant microvascular thrombosis and gastric necrosis. Since this case the physicians and the pharmacy have discontinued prescribing or dispensing Forcalide syrup. This is the first case report implicating Ephedra as the cause of gastrointestinal ischemia and gastric perforation. We strongly recommend that this albeit rare scenario be added as a warning to the list of potential adverse reactions seen with the ingestion of Ephedrine.

![Preoperative abdominal radiograph demonstrated a massively dilated stomach with otherwise normal bowel gas pattern.](crg0004-0079-f01){#F1}

![Intraoperative photograph. The ischemia and necrosis is isolated to the stomach with multiple microperforations noted along the greater curvature.](crg0004-0079-f02){#F2}

###### 

Initial vitals, labs and hemodynamic values at initial presentation to the surgical team

  Initial data at presentation                     Values
  ------------------------------------------------ ------------------------
  Heart rate, beats/min                            103
  Systolic blood pressure, mm Hg                   155
  Diastolic blood pressure, mm Hg                  69
  Temperature, °C                                  35.1
  Central venous pressure, mm Hg                   12
  Pulmonary capillary wedge pressure, mm Hg        21
  Systemic vascular resistance (dynes·sec/cm^5^)   1,457
  Cardiac index, 1/min/BSA                         1.83
  Hemoglobobin, g/dl                               10.6 (ref. 13.5--17.5)
  Leukocytes (×10^9^/l)                            15.4 (ref. 3.5--10.5)
  Platelets (×10^9^/l)                             254 (ref. 150--450)
  Lactate, mmol/1                                  3.9 (ref. 0.6--2.3)

###### 

Test results of the patient\'s Karol-Ephedrine syrup and serum

  Substances screened   Results    
  --------------------- ---------- ----------
  Caffeine              negative   negative
  Cocaine               negative   negative
  Ephedrine             positive   positive
  Efhanol               negative   negative
  Ibuprofen             negative   negative
  Indomefhacin          negative   negative
  Ketoprofen            negative   negative
  Ketorolac             negative   negative
  Lidocaine             negative   negative
  Salicylate            negative   negative
